Ten-year clinical outcome, toxicity and compliance of dose-dense sequential adjuvant administration of cyclophosphamide & amp; epirubicin followed by docetaxel in patients with early breast cancer: A hellenic cooperative oncology group observational study (HE 10/10) with concurrent investigation of significance of tumor infiltrating lymphocytes

CONCLUSIONS: In conclusion, this study confirms the significance of dds adjuvant chemotherapeutic regimen in terms of long-term survival outcome, safety and toxicity as well as the prognostic significance of TILs and infiltrating CD8+ lymphocytes in BC patients with early-stage disease.PMID:38176305 | DOI:10.1016/j.breast.2023.103668

Source: Breast - January 4, 2024 Category: Cancer & Oncology Authors: Foteinos-Ioannis Dimitrakopoulos Anna Goussia Georgia-Angeliki Koliou Katerina Dadouli Anna Batistatou Helen P Kourea Mattheos Bobos Petroula Arapantoni-Dadioti Olympia Tzaida Triantafyllia Koletsa Sofia Chrisafi Maria Sotiropoulou Alexandra Papoudou-Bai Source Type: research